Anavex Life Sciences Corp. (AVXL)
NASDAQ: AVXL · Real-Time Price · USD
8.27
+0.36 (4.55%)
Mar 3, 2025, 4:00 PM EST - Market closed
Anavex Life Sciences Balance Sheet
Financials in millions USD. Fiscal year is October - September.
Millions USD. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 | Sep '21 Sep 30, 2021 | Sep '20 Sep 30, 2020 | 2019 - 2015 |
| Cash & Equivalents | 120.78 | 132.19 | 151.02 | 149.16 | 152.11 | 29.25 | Upgrade
|
| Cash & Short-Term Investments | 120.78 | 132.19 | 151.02 | 149.16 | 152.11 | 29.25 | Upgrade
|
| Cash Growth | -15.99% | -12.47% | 1.25% | -1.94% | 420.04% | 31.84% | Upgrade
|
| Other Receivables | 2.56 | 2.45 | 2.71 | 3.19 | 9.14 | 4.85 | Upgrade
|
| Receivables | 2.56 | 2.45 | 2.71 | 3.19 | 9.14 | 4.85 | Upgrade
|
| Prepaid Expenses | 0.71 | 0.93 | 0.65 | 0.35 | 0.37 | 0.44 | Upgrade
|
| Total Current Assets | 124.04 | 135.57 | 154.39 | 152.71 | 161.62 | 34.54 | Upgrade
|
| Total Assets | 124.04 | 135.57 | 154.39 | 152.71 | 161.62 | 34.54 | Upgrade
|
| Accounts Payable | 4.57 | 9.63 | 4.32 | 3.83 | 4.74 | 3.99 | Upgrade
|
| Accrued Expenses | 7.73 | 4.84 | 7.3 | 5.95 | 5.61 | 3.32 | Upgrade
|
| Current Unearned Revenue | 0.83 | 0.84 | 0.92 | 0.44 | 0.44 | - | Upgrade
|
| Total Current Liabilities | 13.13 | 15.3 | 12.53 | 10.21 | 10.8 | 7.31 | Upgrade
|
| Total Liabilities | 13.13 | 15.3 | 12.53 | 10.21 | 10.8 | 7.31 | Upgrade
|
| Common Stock | 0.09 | 0.09 | 0.08 | 0.08 | 0.08 | 0.06 | Upgrade
|
| Additional Paid-In Capital | 459.01 | 456.25 | 434.84 | 387.98 | 348.33 | 186.85 | Upgrade
|
| Retained Earnings | -348.18 | -336.07 | -293.07 | -245.56 | -197.59 | -159.68 | Upgrade
|
| Shareholders' Equity | 110.92 | 120.26 | 141.85 | 142.49 | 150.82 | 27.24 | Upgrade
|
| Total Liabilities & Equity | 124.04 | 135.57 | 154.39 | 152.71 | 161.62 | 34.54 | Upgrade
|
| Net Cash (Debt) | 120.78 | 132.19 | 151.02 | 149.16 | 152.11 | 29.25 | Upgrade
|
| Net Cash Growth | -15.99% | -12.47% | 1.25% | -1.94% | 420.04% | 31.84% | Upgrade
|
| Net Cash Per Share | 1.44 | 1.58 | 1.89 | 1.94 | 2.18 | 0.50 | Upgrade
|
| Filing Date Shares Outstanding | 85.06 | 84.82 | 82.09 | 77.96 | 76.02 | 66.96 | Upgrade
|
| Total Common Shares Outstanding | 84.99 | 84.8 | 82.07 | 77.94 | 75.92 | 62.05 | Upgrade
|
| Working Capital | 110.92 | 120.26 | 141.85 | 142.49 | 150.82 | 27.24 | Upgrade
|
| Book Value Per Share | 1.31 | 1.42 | 1.73 | 1.83 | 1.99 | 0.44 | Upgrade
|
| Tangible Book Value | 110.92 | 120.26 | 141.85 | 142.49 | 150.82 | 27.24 | Upgrade
|
| Tangible Book Value Per Share | 1.31 | 1.42 | 1.73 | 1.83 | 1.99 | 0.44 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.